These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8614371)

  • 1. Diffuse plasmacytosis in a child with brainstem glioma following multiagent chemotherapy and intensive growth factor support.
    Csáki C; Ferencz T; Sipos G; Kopper L; Schuler D; Borsi JD
    Med Pediatr Oncol; 1996 May; 26(5):367-71. PubMed ID: 8614371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
    Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
    Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo.
    Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM
    Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma.
    Avilés A; Guzmán R; Delgado S; Nambo MJ; García EL; Díaz-Maqueo JC
    Am J Hematol; 1996 Aug; 52(4):275-80. PubMed ID: 8701945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
    Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
    Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.